Obesity problem starts early phase of therapy in children with acute lymphoblastic leukemia

Health Problems

Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and researchers at St. Jude Children’s Research Hospital have discovered that this problem starts during remission-induction treatment and suggests that early intervention should be considered. Chemotherapy drugs to treat ALL contribute to myriad problems, one of which is an increased risk of becoming overweight or obese. And because patients […]

Continue reading »

New investigational antibiotic effective against drug-resistant bacteria in phase 2 trial

Health Problems

Results from a phase 2 randomised trial suggest that a new investigational antibiotic is as effective as the current standard-of-care antibiotic for the treatment of complicated urinary tract infections (UTIs) caused by several multidrug resistant Gram-negative bacteria. The findings, published in The Lancet Infectious Diseases, indicated that patients treated with the siderophore-based drug, cefiderocol, had a higher and more sustained […]

Continue reading »

New compound advances into Phase 1 trial for pancreatic cancer

Health Problems

A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively licensed in 2015 to a private company, DrugCendR Inc. The drug candidate was discovered in the laboratory of Erkki Ruoslahti, M.D., Ph.D., distinguished professor at SBP and founder, […]

Continue reading »

Positive results for phase 1 trial of ivosidenib against AML

Health Problems

Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response. The gene IDH1 […]

Continue reading »

Lupus treatment generates positive results in Phase III clinical trial

Health Problems

New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides considerable benefits to patients with systemic lupus erythematosus (SLE), a predominately female, chronic inflammatory disease that can affect virtually any organ. The Arthritis & Rheumatology findings are encouraging because lupus is among the leading causes of death in young women. SLE is […]

Continue reading »